Corcept Therapeutics Inc (CORT)

Industry Biotechnology
This stock can be held in an Investment ISA and an Investment Account
Sell

$73.54

Buy

$74.36

arrow-up$0.5645 (+0.77%)

Corcept Therapeutics Inc is engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders by modulating the effects of cortisol.
Prices updated at 16 May 2025, 14:39 EDT
| Prices minimum 15 mins delay
|
Prices in USD
NASDAQ
arrow-up0.11%
NASDAQ
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
Our Investment Fees and Charges.

Income statement

Year
chevron-l-regular
chevron-r-regular
20172018201920202021202220232024
159m251m306m354m366m402m482m675m
156m246m301m348m361m396m476m664m
53m89m112m128m124m113m107m137m
33.2035.6236.4136.2334.0128.0322.2420.29
129m75m94m106m113m101m106m141m
53m90m114m130m128m116m110m138m
Sales, General and administrative62m81m100m105m122m153m184m280m
Interest expenses49,000-------
Provision for income taxes-76m17m22m26m12m15m18m20m
Operating expenses103m157m189m220m236m284m369m527m
Income before taxes53m92m117m132m125m116m125m161m
Net income available to common shareholders129m75m94m106m113m101m105m140m
1.140.650.820.920.970.951.021.35
Net interest income-49,0003m5m3m529,0004m17m25m
Advertising and promotion--------
Net investment income, net--------
Realised capital gains (losses), net--------
Total benefits, claims and expenses--------
Earnings per share (diluted)1.040.60.770.850.890.870.941.23
Free cash flow per share0.32830.93310.87781.33441.20171.15721.36441.2803
Book value/share0.75232.25632.91914.19485.09944.38974.46486.0776
Debt equity ratio--0.0051270.000957---0.008986

Balance sheet

Year
chevron-l-regular
chevron-r-regular
20172018201920202021202220232024
Current assets124m237m307m479m266m499m459m472m
Current liabilities30m36m39m47m48m72m105m141m
Total capital191m276m371m523m376m502m507m680m
Total debt--3m3m526,0001m151,0007m
Total equity191m276m371m523m376m502m507m680m
Total non current liabilities--------
Loans--------
Total assets221m312m412m572m424m583m622m841m
Total liabilities--------
Cash and cash equivalents31m42m31m76m78m66m136m128m
Common stock115m115m115m117m106m108m103m105m

Cash flow

Year
chevron-l-regular
chevron-r-regular
20172018201920202021202220232024
Cash at beginning of period52m31m42m31m76m78m66m136m
Cash dividends paid--------
61m115m135m151m167m120m127m196m
Investments (gains) losses-73m-91m-118m-119m136m-114m91m-178m
31m42m31m76m78m66m136m128m
Net income--------
61m116m136m152m168m120m127m198m
-419,000-298,000-1m-1m-469,000-413,000-139,000-2m
The figures shown in the tables are quoted in the currency of the stock selected.
Please note that past performance is not a reliable indicator of future returns. Please use the interactive graph for benchmark comparison.


Important Information

Please note the value of investments can go down as well as up so you may get back less than you invested. This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to an authorised financial adviser. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and(3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
© Copyright 2025 Morningstar. All rights reserved.